Novel Use of GLP-1 Receptor Agonist Therapy in HNF4A-MODY
نویسندگان
چکیده
منابع مشابه
Case Study: Use of GLP-1 Receptor Agonist in a Patient on Intensive Insulin Therapy
Current treatment of type 2 diabetes begins with diet and lifestyle modifications accompanied by use of oral antihyperglycemic medications. Despite multiple therapeutic options for people with type 2 diabetes, the disorder continues to progress, resulting in the gradual deterioration of glycemic control over time (1). This is the result of insulin resistance and progressive decline in β-cell fu...
متن کاملNovel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist
GLP-1 has a variety of anti-diabetic effects. However, native GLP-1 is not suitable for therapy of diabetes due to its short half-life (t1/2<2 min). To circumvent this, we developed a long-lasting GLP-1 receptor agonist by the fusion of GLP-1 with human IgG2 Fc (GLP-1/hIgG2). ELISA-based receptor binding assay demonstrated that GLP-1/hIgG2 had high binding affinity to the GLP-1R in INS-1 cells ...
متن کاملPrediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes
BACKGROUND Glucagon-like peptide-1 (GLP-1) receptor agonists can maintain good glycemic control in some diabetic. Here we compared the clinical characteristics and parameters reflecting glucose metabolism at the time of the initiation of GLP-1 receptor agonist therapy between patients who responded well to therapy and those who did not. METHODS The records of 43 patients with type 2 diabetes ...
متن کاملIdentification of HNF1A-MODY and HNF4A-MODY in Irish families: phenotypic characteristics and therapeutic implications.
AIM The prevalence of hepatocyte nuclear factor (HNF)-1A and HNF4A mutations, and the clinical implications following the genetic diagnosis of maturity-onset diabetes of the young (MODY) in the Irish population, remain unknown. The aim of this study was to establish the occurrence of HNF1A and HNF4A mutations in subjects classified clinically as MODY to identify novel mutations, and to determin...
متن کاملExpression and Characterization of a Potent Long-Acting GLP-1 Receptor Agonist, GLP-1-IgG2σ-Fc
Human GLP-1 (glucagon-like peptide-1) can produce a remarkable improvement in glycemic control in patients with type 2 diabetes. However, its clinical benefits are limited by its short half-life, which is less than 2 min because of its small size and rapid enzymatic inactivation by dipeptidyl peptidase IV. We engineered GLP-1-IgG2σ-Fc, a 68-kDa fusion protein linking a variant human GLP-1 (A8G/...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Diabetes Care
سال: 2020
ISSN: 0149-5992,1935-5548
DOI: 10.2337/dc20-0012